G. Carter

G. Carter, K. Mollison, R. Krause, 1981, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitis.

S. Davidsen, C. Wegner, P. Tapang, 1998, The Journal of pharmacology and experimental therapeutics.

The 5-lipoxygenase inhibitory activity of zileuton in in vitro and in vivo models of antigen-induced airway anaphylaxis.

J. Summers, D. W. Brooks, G. Carter, 1994, Pulmonary pharmacology.

Characterization of A-93178, an Iminoxy-Quinoline

J. Bouska, G. Carter, K. Hulkower, 1997 .

Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonist.

S. Davidsen, P. Tapang, D. Albert, 1997, European journal of pharmacology.

Lipopolysaccharide-induced changes in plasma nitrite and nitrate concentrations in rats and mice: pharmacological evaluation of nitric oxide synthase inhibitors.

G. Carter, W. R. Tracey, J. Tse, 1995, The Journal of pharmacology and experimental therapeutics.

trans-Activation and repression properties of the novel nonsteroid glucocorticoid receptor ligand 2,5-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5-(1-methylcyclohexen-3-y1)-1H-[1]benzopyrano[3,4-f]quinoline (A276575) and its four stereoisomers.

M. Nakane, J. Kuk, G. Carter, 2002, Molecular pharmacology.

A macrolactam inhibitor of T helper type 1 and T helper type 2 cytokine biosynthesis for topical treatment of inflammatory skin diseases.

J. Trevillyan, G. Carter, K. Marsh, 1999, The Journal of investigative dermatology.

The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor.

P. Young, D. Albert, J. Summers, 1992, International journal of immunopharmacology.

Stereoselective Metabolism of the 5‐Lipoxygenase Inhibitor A‐78773

L. Dubé, R. Hansen, J. Bouska, 1994, Annals of the New York Academy of Sciences.

Ex vivo inhibition of PAF-induced beta-thromboglobulin release in man by ABT-299, a potent PAF antagonist.

D. Albert, J. Summers, G. Carter, 1996, Advances in experimental medicine and biology.

ABT-761 attenuates bronchoconstriction and pulmonary inflammation in rodents.

J. Bouska, G. Carter, K. Hulkower, 1997, The Journal of pharmacology and experimental therapeutics.

Synthesis of bicyclic thiazolidine PAF antagonists

S. Davidsen, J. Summers, G. Carter, 1993 .

The Discovery of Zileuton (Leutrol

D. W. Brooks, G. Carter, 1995 .

Ex vivo inhibition of β-thromboglobulin release following administration to man of ABT-299, a novel prodrug of a potent platelet activating factor antagonist

D. Albert, J. Summers, G. Carter, 1997, Inflammation Research.

Chapter 8. Pulmonary and Antiallergy Agents

D. W. Brooks, G. Carter, R. Bell, 1988 .

The properties of A-69412: A small hydrophilic 5-lipoxygenase inhibitor

P. Young, J. Summers, J. Bouska, 2005, Agents and Actions.

Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors.

J. Bouska, D. W. Brooks, G. Carter, 1995, The Journal of pharmacology and experimental therapeutics.

Structure-function studies in a series of carboxyl-terminal octapeptide analogues of anaphylatoxin C5a.

G. Carter, D. Quincy, K. Mollison, 1992, Journal of medicinal chemistry.

Improving the in vivo duration of 5-lipoxygenase inhibitors: application of an in vitro glucuronosyltransferase assay.

C. Goodfellow, G. Carter, J. Bouska, 1997, Drug metabolism and disposition: the biological fate of chemicals.

TH1 and TH2 cytokine inhibition by 3,5-bis(trifluoromethyl)pyrazoles, a novel class of immunomodulators.

Julie A. Wilkins, U. Warrior, M. Nakane, 2002, Cellular immunology.

Preliminary in vivo pharmacokinetic and pharmacodynamic evaluation of a novel calcineurin-independent inhibitor of NFAT

U. Christians, R. Morris, W. Jacobsen, 2004, Transplant international : official journal of the European Society for Organ Transplantation.

Preliminary in vivo pharmacokinetic and pharmacodynamic evaluation of a novel calcineurin‐independent inhibitor of NFAT

U. Christians, R. Morris, W. Jacobsen, 2004 .

Inhibition of leukotriene biosynthesis in the rat peritoneal cavity.

P. Young, J. Summers, D. W. Brooks, 1991, European journal of pharmacology.

1-Phenyl-[2H]-tetrahydropyridazin-3-one, A-53612, a selective orally active 5-lipoxygenase inhibitor

P. Young, D. Albert, J. Bouska, 1992 .

Structural analysis of 2-aryl-1,3-dione compounds as inhibitors of 5-lipoxygenase

R. D. Dyer, P. Young, R. Dyer, 1992 .

O-alkylcarboxylate oxime and N-hydroxyurea analogs of substituted indole leukotriene biosynthesis inhibitors

R. Maki, P. Young, J. Bouska, 1996 .

The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits

S. Mitchell, J. Witkin, D. Schoepp, 2016, The Journal of Pharmacology and Experimental Therapeutics.

A-78773: a selective, potent 5-lipoxygenase inhibitor.

P. Young, J. Bouska, D. W. Brooks, 1993, Journal of lipid mediators.

Induction of prostaglandin H synthase-2 and tumor necrosis factor-alpha in human amnionic WISH cells by various stimuli occurs through distinct intracellular mechanisms.

K. Glaser, G. Carter, K. Hulkower, 1997, The Journal of pharmacology and experimental therapeutics.

Heinz bodies, methemoglobinemia, and hemolytic anemia induced in rats by 3-amino-1-[m-(trifluoromethyl)phenyl]-2-pyrazoline.

G. Carter, J. Kesterson, I. Heyman, 1984, Fundamental and applied toxicology : official journal of the Society of Toxicology.

Novel potent and selective inhibitors of inducible nitric oxide synthase.

M. Nakane, J. Pollock, J. Kuk, 1995, Molecular pharmacology.

Functional expression of three isoforms of human nitric oxide synthase in baculovirus-infected insect cells.

H. Esumi, M. Nakane, J. Pollock, 1995, Biochemical and biophysical research communications.

Hydroxamic acid inhibitors of 5-lipoxygenase.

R. D. Dyer, J. Summers, H. Mazdiyasni, 1987, Journal of medicinal chemistry.

Structure-activity relationships of the pyridazinone series of 5-lipoxygenase inhibitors

P. Young, D. Albert, R. Dyer, 1992 .

Purification of a mammalian 5-lipoxygenase from rat basophilic leukemia cells.

A. Goetze, G. Carter, D. Bornemeier, 1985, Prostaglandins.

In vivo pharmacological evaluation of two novel type II (inducible) nitric oxide synthase inhibitors.

M. Nakane, G. Carter, W. R. Tracey, 1995, Canadian journal of physiology and pharmacology.

High-level C5a gene expression and recovery of recombinant human C5a fromEscherichia coli

G. Carter, J. L. Fox, K. Mollison, 1987, Agents and Actions.

2-[(Phenylthio)methyl]pyridine derivatives: new antiinflammatory agents.

P. Young, F. Haviv, G. Carter, 1983, Journal of medicinal chemistry.

ABT-963 [2-(3,4-Difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], A Highly Potent and Selective Disubstituted Pyridazinone Cyclooxgenase-2 Inhibitor

G. Carter, S. Surapaneni, K. Marsh, 2004, Journal of Pharmacology and Experimental Therapeutics.

3-[1-(2-Benzoxazolyl)hydrazino]propanenitrile derivatives: inhibitors of immune complex induced inflammation.

P. Young, F. Haviv, G. Carter, 1988, Journal of medicinal chemistry.

Synthesis and structure-activity relationships of a series of novel benzopyran-containing platelet activating factor antagonists.

D. Albert, J. Summers, G. Carter, 1992, Journal of medicinal chemistry.

2-((PHENYLTHIO)METHYL)PYRIDINE DERIVATIVES: NEW ANTIINFLAMMATORY AGENTS

P. Young, F. Haviv, G. Carter, 1983 .

Design of inhibitors of leukotriene biosynthesis and their therapeutic potential

J. Bouska, G. Carter, R. Harris, 1998 .

Quantitative structure-activity relationships of 5-lipoxygenase inhibitors. Inhibitory potency of pyridazinone analogues.

Y. Martin, R. Dyer, D. W. Brooks, 1994, Journal of pharmaceutical sciences.

Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors.

R. Maki, P. Young, J. Summers, 1997, Journal of medicinal chemistry.

Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships.

R. D. Dyer, J. Summers, H. Mazdiyasni, 1990, Journal of medicinal chemistry.

Measurement of inflammatory reactions by a dye dilution method

P. Young, G. Carter, K. Mollison, 1982, The Journal of pharmacy and pharmacology.

Symmetrical bis(heteroarylmethoxyphenyl)alkylcarboxylic acids as inhibitors of leukotriene biosynthesis.

J. Bouska, G. Carter, K. Hulkower, 2000, Journal of medicinal chemistry.

Synthesis and 5-lipoxygenase inhibitory activity of 5-hydroperoxy-6,8,11,14-eicosatetraenoic acid analogues.

R. Dyer, D. W. Brooks, G. Carter, 1987, Journal of medicinal chemistry.

N-(acyloxyalkyl)pyridinium salts as soluble prodrugs of a potent platelet activating factor antagonist.

S. Davidsen, D. Albert, J. Summers, 1994, Journal of medicinal chemistry.

Pharmacological studies in the rat with [2-(2,3-didecanoyloxy)-propyl]2-acetyloxybenzoate (A-45474): An aspirin pro-drug with negligible gastric irritation

P. Young, G. Carter, G. Y. Paris, 1980, Agents and Actions.

A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects.

M. Nakane, S. Elmore, R. Turner, 2003, Molecular endocrinology.

ATTENUATION OF ENDOTOXIN‐INDUCED PATHOPHYSIOLOGY BY A NEW POTENT PAF RECEPTOR ANTAGONIST

D. Albert, K. Kruse-Elliott, J. Zimmerman, 1996, Shock.

The role of tissue mast cells in polyacrylamide gel-induced inflammation in mice

G. Carter, D. Wilcox, R. Harris, 1998, Inflammation Research.

Structural requirements for the inhibition of 5-lipoxygenase by 15-hydroxyeicosa-5,8,11,13-tetraenoic acid analogues.

R. D. Dyer, Y. Martin, F. Haviv, 1987, Journal of medicinal chemistry.

4-hydroxythiazole inhibitors of 5-lipoxygenase.

R. D. Dyer, R. Dyer, D. W. Brooks, 1991, Journal of medicinal chemistry.

5-lipoxygenase inhibitory activity of zileuton.

R. D. Dyer, P. Young, D. Albert, 1991, The Journal of pharmacology and experimental therapeutics.

Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive N-Methyl-d-Aspartate Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists, for the Treatment of Depression.

P. Ornstein, V. Tolstikov, S. Mitchell, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors.

J. Summers, J. Bouska, G. Carter, 1997, Journal of medicinal chemistry.

Sequence-specific assignments in the 1H NMR spectrum of the human inflammatory protein C5a.

E. Zuiderweg, J. Henkin, G. Carter, 1988, Biochemistry.

Leukotrienes and α-naphthylisothiocyanate-induced liver injury

M. Peters-Golden, R. Roth, G. Carter, 1995 .

Zotarolimus, a Novel Sirolimus Analogue With Potent Anti-proliferative Activity on Coronary Smooth Muscle Cells and Reduced Potential for Systemic Immunosuppression

Yung-wu Chen, J. Trevillyan, G. Carter, 2007, Journal of cardiovascular pharmacology.

Glycerides as prodrugs. 2. 1,3-Dialkanoyl-2-(2-methyl-4-oxo-1,3-benzodioxan-2-yl)glycerides (cyclic aspirin triglycerides) as antiinflammatory agents.

P. Young, G. Carter, D. Garmaise, 1980, Journal of medicinal chemistry.

Glycerides as prodrugs. 1. Synthesis and antiinflammatory activity of 1,3-bis(alkanoyl)-2-(O-acetylsalicyloyl)glycerides (aspirin triglycerides).

P. Young, G. Carter, D. Garmaise, 1979, Journal of medicinal chemistry.

5-Lipoxygenase inhibitors: synthesis and structure-activity relationships of a series of 1-aryl-2H,4H-tetrahydro-1,2,4-triazin-3-ones.

P. Young, B. Gunn, J. Bouska, 1996, Journal of medicinal chemistry.

propane : An Iodinated Radioligand That Specifically Labels the Agonist High-Affinity State of 5-HT 2 Serotonin Receptors

P. Young, J. Summers, B. Gunn, 2022 .

Comparison of model and nuclear magnetic resonance structures for the human inflammatory protein C5a

J. Greer, E. Zuiderweg, J. Henkin, 1988, Proteins.

Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonist.

S. Davidsen, P. Tapang, D. Albert, 1996, The Journal of pharmacology and experimental therapeutics.

Eicosatetraenehydroxamates: inhibitors of 5-lipoxygenase

R. D. Dyer, R. Dyer, G. Carter, 1985 .

The nitric oxide synthase inhibitor, L-NG-monomethylarginine, reduces carrageenan-induced pleurisy in the rat.

M. Nakane, J. Kuk, G. Carter, 1995, The Journal of pharmacology and experimental therapeutics.

The effects of anti-inflammatory and other agents on the rat dermal arthus reaction.

P. Young, G. Carter, R. Krause, 1982, Research communications in chemical pathology and pharmacology.

Heteroarylmethoxyphenylalkoxyiminoalkylcarboxylic acids as leukotriene biosynthesis inhibitors.

J. Bouska, G. Carter, K. Hulkower, 2000, Journal of medicinal chemistry.

(R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor.

J. Bouska, G. Carter, P. Bhatia, 1995, Journal of medicinal chemistry.

Rapamycin analogs with reduced systemic exposure.

P. Wiedeman, J. Trevillyan, G. Carter, 2005, Bioorganic & medicinal chemistry letters.

High-level expression of a gene encoding the human complement factor C5a in Escherichia coli.

G. Carter, J. L. Fox, K. Mollison, 1986, Gene.

Comparative Effects of LY3020371, a Potent and Selective mGlu2/3 Receptor Antagonist, and Ketamine, a Non-Competitive NMDA Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists for the Treatment of Depression

V. Tolstikov, S. Mitchell, G. Gilmour, 2017 .

Synthesis and 5‐Lipoxygenase Inhibitory Activity of 5‐Hydroperoxy‐ 6,8,11,14‐eicosatetraenoic Acid Analogues.

R. D. Dyer, D. W. Brooks, G. Carter, 1987 .

Identification and synthesis of a receptor binding site of human anaphylatoxin C5a.

G. Carter, D. Quincy, K. Mollison, 1991, Journal of medicinal chemistry.

ABT-963, A Highly Potent and Selective Disubstituted Pyridazinone COX-2 Inhibitor

G. Carter, S. Surapaneni, M. Jarvis, 2004 .